Literature DB >> 27734591

The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication.

Suzanne Di Capite1, Rachel Upthegrove1,2, Pavan Mallikarjun1,2,3.   

Abstract

BACKGROUND: To determine the "real world" relapse rate in patients with first-episode psychosis (FEP) who had discontinued antipsychotic medication and identify socio-demographic and clinical factors associated with the risk of relapse.
METHODS: Quantitative data were obtained via case-note review on 63 patients with FEP who had discontinued antipsychotic medication from Birmingham Early Intervention Service between 2012 and 2015. The follow-up period was until either: an occurrence of a relapse; end of 12-month study period; end of patient's case-note record. Relapse was defined as a return of symptoms requiring one of the following: home treatment, hospital admission or was based on clinical teams' decision as having a relapse. A pro-forma targeted pre-defined socio-demographic and clinical factors. Survival analysis was undertaken to estimate the 12-month relapse rate following discontinuation of antipsychotics and Cox regression performed to identify relapse predictors.
RESULTS: The Kaplan-Meier 12-month relapse estimate was 67% (95% confidence interval, 54%, 80%). Significant factors (P < .05) independently associated with an increased risk of relapse following discontinuation of antipsychotic medication were: male gender, not being in education, employment or training (NEET) and number of previous psychiatric hospital admissions.
CONCLUSIONS: Relapse is common after discontinuation of antipsychotic medication following recovery from a FEP. It is important that patients who wish to discontinue their medication are informed of the high relapse rates and the associated risks. Furthermore, male patients, patients with NEET status and those who have had previous hospital admissions may require closer monitoring.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  antipsychotics; discontinuation; first-episode psychosis; relapse; risk factors

Mesh:

Substances:

Year:  2016        PMID: 27734591     DOI: 10.1111/eip.12385

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  11 in total

1.  Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting.

Authors:  Nicola Poloni; Marta Ielmini; Ivano Caselli; Giulia Lucca; Alessandra Gasparini; Alessandra Gasparini; Giorgia Lorenzoli; Camilla Callegari
Journal:  Psychopharmacol Bull       Date:  2019-06-20

2.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

3.  Characteristics of Inpatients Prescribed Dopamine Receptor Blocking Agents.

Authors:  Shaina Schwartz; Lauren Dinkla; Jocelyn Pullen; Rachel Bernard; Archana Kumar
Journal:  Psychopharmacol Bull       Date:  2021-11-03

4.  Prediction of Early Symptom Remission in Two Independent Samples of First-Episode Psychosis Patients Using Machine Learning.

Authors:  Rigas F Soldatos; Micah Cearns; Mette Ø Nielsen; Costas Kollias; Lida-Alkisti Xenaki; Pentagiotissa Stefanatou; Irene Ralli; Stefanos Dimitrakopoulos; Alex Hatzimanolis; Ioannis Kosteletos; Ilias I Vlachos; Mirjana Selakovic; Stefania Foteli; Nikolaos Nianiakas; Leonidas Mantonakis; Theoni F Triantafyllou; Aggeliki Ntigridaki; Vanessa Ermiliou; Marina Voulgaraki; Evaggelia Psarra; Mikkel E Sørensen; Kirsten B Bojesen; Karen Tangmose; Anne M Sigvard; Karen S Ambrosen; Toni Meritt; Warda Syeda; Birte Y Glenthøj; Nikolaos Koutsouleris; Christos Pantelis; Bjørn H Ebdrup; Nikos Stefanis
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

5.  Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.

Authors:  José Manuel Olivares; Andrea Fagiolini
Journal:  Front Psychiatry       Date:  2022-04-28       Impact factor: 5.435

6.  Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.

Authors:  José Manuel Olivares; Ana González-Pinto; Mario Páramo
Journal:  Eur Psychiatry       Date:  2021-04-12       Impact factor: 5.361

7.  Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study.

Authors:  Rafal A H Yeisen; Jone Bjornestad; Inge Joa; Jan Olav Johannessen; Stein Opjordsmoen
Journal:  BMC Psychiatry       Date:  2017-08-22       Impact factor: 3.630

8.  Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.

Authors:  Paola Bozzatello; Silvio Bellino; Paola Rocca
Journal:  Front Psychiatry       Date:  2019-02-26       Impact factor: 4.157

9.  Healthcare Provider Engagement with a Novel Dashboard for Tracking Medication Ingestion: Impact on Treatment Decisions and Clinical Assessments for Adults with Schizophrenia.

Authors:  Jeffrey M Cochran; Hui Fang; John G Sonnenberg; Elan A Cohen; Jean-Pierre Lindenmayer; J Corey Reuteman-Fowler
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-28       Impact factor: 2.989

10.  Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis.

Authors:  Seoyoung Kim; Sang Ho Shin; Barbara Santangelo; Mattia Veronese; Seung Kwan Kang; Jae Sung Lee; Gi Jeong Cheon; Woojoo Lee; Jun Soo Kwon; Oliver D Howes; Euitae Kim
Journal:  Mol Psychiatry       Date:  2020-09-14       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.